BEDFORD, Mass.--(BUSINESS WIRE)--Aug. 29, 2018--
Ocular Therapeutix, Inc. (NASDAQ:OCUL) a biopharmaceutical company
focused on the formulation, development, and commercialization of
innovative therapies for diseases and conditions of the eye, today
announced that Antony Mattessich, President and Chief Executive Officer
of Ocular Therapeutix, will present at the H.C. Wainwright 20th Annual
Global Investment Conference on Thursday, September 6, 2018 at 1:45 PM
ET at the St. Regis New York Hotel in New York, NY.
In addition to the presentation, the management team will host investor
meetings at the conference. Investors attending the conference who are
interested in meeting with Ocular Therapeutix management should contact
their H.C. Wainwright representative.
A live webcast of the presentation can be accessed by visiting the
Investors section of the Company’s website at investors.ocutx.com.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the
formulation, development, and commercialization of innovative therapies
for diseases and conditions of the eye using its proprietary
bioresorbable hydrogel-based formulation technology. Ocular
Therapeutix’s lead product candidate, DEXTENZA®
(dexamethasone insert), has completed Phase 3 clinical development for
the treatment of ocular pain and inflammation following ophthalmic
surgery. The New Drug Application (NDA) for DEXTENZA has a target action
date under the FDA Prescription Drug User Fee Act, or PDUFA, of December
28, 2018. OTX-TP (travoprost insert) is an intracanalicular insert in
Phase 3 clinical development for the reduction of intraocular pressure
in patients with primary open-angle glaucoma and ocular hypertension.
The Company’s earlier stage assets include OTX-TIC, an extended-delivery
travoprost intracameral implant for the reduction of intraocular
pressure in patients with glaucoma and ocular hypertension, as well as
sustained release intravitreal implants for the treatment of retinal
diseases. These intravitreal implants include the development of
OTX-TKI, a tyrosine kinase inhibitor (TKI), and, in collaboration with
Regeneron, OTX-IVT, an extended-delivery protein-based anti-vascular
endothelial growth factor (VEGF) trap. Ocular Therapeutix's first
product, ReSure® Sealant, is FDA-approved to seal corneal
incisions following cataract surgery.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180829005130/en/
Source: Ocular Therapeutix, Inc.
Chris Brinzey, 339-970-2843
Senior Vice President, Commercial